Clinical Trials Sponsored by ARMO BioSciences

Total 2882 results

Leadiant Biosciences, Inc.

Active, not recruiting

A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)

Cerebrotendinous Xanthomatoses

Israel
Chipscreen Biosciences, Ltd.

Completed

Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

China
Arcus Biosciences, Inc.

Completed

A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers (ARC-26)

Cancer

United Kingdom
Arcus Biosciences, Inc.

Completed

A Study to Investigate the Safety of AB680 in Healthy Volunteers

Healthy Volunteers

Australia
Arcus Biosciences, Inc.

Completed

A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers

Healthy Volunteers

Australia
Arcus Biosciences, Inc.

Completed

A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

Colorectal Cancer | GastroEsophageal Cancer

United States, Australia
Venn Biosciences Corporation

Completed

Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy (VOCAL)

Ovarian Cancer | Adnexal Mass | Pelvic Mass

Philippines, United States, Malaysia, Australia
IGM Biosciences, Inc.

No longer available

Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL

Relapsed/Refractory Non-Hodgkin Lymphomas

Australia, Korea, Republic of, Spain
Brii Biosciences Limited

Completed

A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)

Severe Postpartum Depression

United States
KBP Biosciences
Covance

Completed

Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects

Healthy | Drug Drug Interaction

United States
KBP Biosciences
Covance

Completed

A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects

Healthy

United States
KBP Biosciences
Covance

Completed

Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

Healthy | Moderate Hepatic Impairment

United States
Chipscreen Biosciences, Ltd.

Completed

A Clinical Trial of CS12192 in Healthy Subjects

Healthy

China
Modern Biosciences Ltd

Completed

Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA

Rheumatoid Arthritis

Bosnia and Herzegovina, Bulgaria, Chile, Czechia, Guatemala, Mexico, Poland, Serbia
Ventyx Biosciences, Inc

Terminated

VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)

Psoriatic Arthritis

United States, Bulgaria, Czechia, Germany, Hungary, Poland, Spain
Ventyx Biosciences, Inc

Terminated

VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis (Serenity PsO)

Psoriasis

Poland, United States, Canada
Sagimet Biosciences Inc.

Completed

Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Fatty Liver Disease

United States, Canada, Puerto Rico, Poland
Aptose Biosciences Inc.

Active, not recruiting

A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Clexio Biosciences Ltd.

Completed

A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study

Adjunctive Treatment of Major Depressive Disorder

United States, Puerto Rico
Selecta Biosciences, Inc.

Completed

A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy (COMPARE)

Chronic Gout

United States
Solid Biosciences Inc.

Active, not recruiting

Microdystrophin Gene Transfer Study in Adolescents and Children With DMD (IGNITE DMD)

Duchenne Muscular Dystrophy

United States
Kashiv BioSciences, LLC

Completed

Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study

Metastatic Breast Cancer

Jordan
Harmony Biosciences, LLC

Active, not recruiting

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Prader-Willi Syndrome

United States
GreenLight Biosciences, Inc.

Withdrawn

A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster

COVID-19
Solid Biosciences Inc.

Completed

Evaluation of Home Based Assessments on Participants With DMD

Duchenne Muscular Dystrophy

United States
Whitecap Biosciences, LLC

Completed

Safety and IOP-Lowering Effects of WB007

Ocular Hypertension | Glaucoma, Primary Open Angle

United States
Senhwa Biosciences, Inc.

Active, not recruiting

Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

Carcinoma, Basal Cell

United States
Calithera Biosciences, Inc

Terminated

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Squamous Non-small-cell Lung Cancer | NFE2L2 Gene Mutation | Squamous Non-Small Cell Neoplasm of Lung

United States
Evelo Biosciences, Inc.

Completed

Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms

Healthy | Disintegration

United Kingdom
Calithera Biosciences, Inc

Terminated

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Clear Cell Renal Cell Carcinoma (ccRCC)

United States
Calithera Biosciences, Inc

Terminated

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

Non-Small Cell Lung Cancer | Non-squamous Non-small-cell Lung Cancer | Non-Squamous Non-Small Cell Neoplasm of Lung | KEAP1 Gene Mutation | NFE2L2 Gene Mutation | NRF2 Mutation

United States
Evopoint Biosciences Inc.

Completed

Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects

Bacterial Infections

United States
Calithera Biosciences, Inc

Completed

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Large B-cell, Diffuse

United States, Canada, Germany
Calithera Biosciences, Inc

Withdrawn

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

Lymphoma, Malignant | Advanced Solid Neoplasms

United States
Calithera Biosciences, Inc

Terminated

A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

Lymphoma, Non-Hodgkin | Lymphoma, Follicular, Marginal Zone

Korea, Republic of, Japan
Calithera Biosciences, Inc

Terminated

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States, Canada
Calithera Biosciences, Inc

Completed

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

Breast Neoplasms

United States, Spain
Evelo Biosciences, Inc.

Completed

Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma

Psoriasis | Asthma | Atopic Dermatitis

United Kingdom
Cellectar Biosciences, Inc.

Completed

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

Non Small Cell Lung Cancer

United States, Israel, Canada, Spain, Russian Federation, Serbia, Italy, Poland, Romania, Switzerland, Ukraine, United Kingdom
Calithera Biosciences, Inc

Completed

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Renal Cell Carcinoma | Non Small Cell Lung Cancer | Mesothelioma | Solid Tumors | Triple-Negative Breast Cancer | Fumarate Hydratase (FH)-Deficient Tumors | Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST) | Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal... and other conditions

United States
Pardes Biosciences, Inc.

Completed

Study of PBI-0451 in Healthy Subjects.

Covid19

New Zealand
Castle Biosciences Incorporated

Completed

5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes (CLEAR)

Uveal Melanoma
Dyve Biosciences, Inc.

Completed

Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS) (TARGETS)

Gout

United States
Knopp Biosciences
Biogen

Terminated

Phase 3 Extension Study of Dexpramipexole in ALS (ENVISION)

Amyotrophic Lateral Sclerosis

United States, United Kingdom, Netherlands, Spain, Belgium, Germany, Australia, Sweden, France, Ireland, Canada
Genocea Biosciences, Inc.

Completed

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

Renal Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Urothelial Carcinoma | Cutaneous Melanoma

United States
Keymed Biosciences Co.Ltd

Completed

Single Ascending Dose Study of CM326 in Healthy Volunteers

Asthma

China
Evelo Biosciences, Inc.

Completed

A Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis

Psoriasis | Atopic Dermatitis

United Kingdom
Liminal BioSciences Ltd.

Completed

A Healthy Volunteer Study of PBI-4050

Fibrosis | Inflammation

United Kingdom
Cogent Biosciences, Inc.

Terminated

Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product

Multiple Myeloma | Solid Tumor | HER-2 Protein Overexpression | B Cell Lymphomas

United States
Cogent Biosciences, Inc.

Terminated

Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma

Lymphoma

United States

Clinical Trials Sponsored by ARMO BioSciences

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations